Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Calimmune, Inc.
CSL Looks Beyond Organic Growth To External Innovation
CSL Ltd.'s sales grew 15% in its last fiscal year and are expected to grow about 8% in FY 2018, but the Australia-based company is looking beyond its plasma protein expertise to outside innovation to help boost future revenue.
Deals Shaping The Medical Industry, September 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
Deal Watch: CSL Behring's Calimmune Buy Builds On Its Base & Adds Platform Tech
Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.
Execs On The Move, January 2017
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.